Vir Biotechnology (VIR) Q3 2024 earnings summary

Executive summary

• Closed an exclusive worldwide licensing agreement with Sanofi, adding three clinical-stage masked T-cell engagers and the PRO-XTEN platform to the pipeline, with a $100–$103.7 million upfront payment.

• Announced strategic restructuring, including a 25% workforce reduction, closure of R&D sites, and phase-out of influenza, COVID-19, and viral vector programs to prioritize hepatitis and oncology pipelines.

• Advanced hepatitis delta (HDV) and hepatitis B (HBV) programs, with key Phase 2 data readouts and regulatory engagement planned for late 2024 and 2025.

• Appointed Jason O’Byrne as Chief Financial Officer, effective October 2, 2024, emphasizing disciplined capital deployment.

• Revenue remains limited, with negative collaboration revenue from sotrovimab and lower grant and contract revenue compared to prior periods.

Financial highlights

• Q3 2024 R&D expenses were $195.2 million, up from $145 million in Q3 2023, mainly due to the Sanofi transaction.

• SG&A expenses decreased to $25.7 million from $40.9 million year-over-year, reflecting cost-saving initiatives.

• Q3 2024 total revenues were $2.4 million, down from $2.6 million year-over-year.

• Net loss was $213.7 million ($1.56 per share) in Q3 2024, compared to $163.4 million ($1.22 per share) in Q3 2023.

• Cash, cash equivalents, and investments totaled $1.19 billion as of September 30, 2024, down $245.1 million from the previous quarter, supporting operations for at least 12 months.

Outlook and guidance

• Updated 2024 GAAP operating expense guidance to $660–$680 million, reflecting the Sanofi upfront payment, stock-based compensation, and restructuring charges.

• Key HDV and HBV data to be presented at AASLD in November 2024, with further updates and functional cure data expected in Q2 2025.

• Initial clinical data for T-cell engager programs anticipated in Q1 2025.

• Annual workforce cost savings of ~$50 million expected starting in 2025 due to restructuring.

• Management expects continued net losses as the company advances its hepatitis and oncology pipelines.